Operational Benchmarks for Psychedelic Care
December 2025’s studies add practical detail to a shift already underway: psychedelic care is moving from “can it work” to “how do we deliver it safely, consistently, and in a way payers can cover.”
Microdosing Shows Minimal Effects While Macrodose Studies Continue to Impress
November 2025 delivered a sharp reality check for psychedelic microdosing while macrodose studies advanced treatment options for depression, PTSD, and end-of-life distress.
Veterans, Microdosing, and Faster Psilocybin Timelines
Psychedelic Policy News from November 2025 where we cover veterans getting access, faster psilocybin approval, and micro(dosing) results.
Unlocking Safe Ibogaine Care
In this Delphi Insight Session, Lia Mix shares her journey with trauma and healing, and how Delphi and IHPI are advancing Ibogaine therapy.
Real-World Data Sharpen the Case for Safe and Effective Psychedelic Therapies
New psychedelic studies from October show 5-year safety data from esketamine, the importance of set & setting, and microdosing null-results.
New Psychedelic Studies Advance Clinical Applications
New psychedelic studies from September show psilocybin for addiction, LSD for anxiety, and group therapy for burnout, guiding clinical and policy integration.
Tracking Real World Psychedelic Use Nationwide
Kate Reynolds from Rocky Mountain Poison and Drug Safety (RPMDS) discusses how NSIHT tracks real world psychedelic use nationwide.
Psychedelics and Reimbursement in Europe
Join Lia Mix, CEO of Delphi, and Floris Wolswijk, Senior Policy and Research Partner at Delphi, for the third Delphi Insight Session on reimbursement pathways for psychedelic therapies in Europe.
Economic, Clinical, and Real-world Insights
The latest research on psychedelic-assisted therapies in August provides critical insights into economic feasibility, implementation models, and clinical effectiveness across diverse patient groups.
Cross-Diagnostic Potential of Psychedelics
New psychedelic studies highlight cross-indication applicability of MDMA-assisted therapy, risks with naturalistic use, and potential life-extending effects of psilocybin.
